Neil Desai compensation by year
Whitehawk Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Salary | $465,791 | $618,120 | $638,040 |
| Bonus | $394,000 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $2,511,538 | $1,934,692 | $1,451,968 |
| Non-equity incentive | $315,000 | $500,000 | $72,306 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $53,939 | $0 | $0 |
| Total | $3,740,268 | $3,052,812 | $2,162,314 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Whitehawk Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0001628280-24-018546, and prior-year filings.
How this page was built: the Whitehawk Therapeutics, Inc. filed document, accession 0001628280-24-018546. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 5,947 | — | $3.41 |
| Option | 150,000 | — | $12.31 |
| Option | 89,425 | — | $17.24 |
| Option | 54,688 | — | $27.67 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Whitehawk Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2023 proxy (filed April 26, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-12 | Grant or award derivative | — | 38,040 | $0.00 | 38,040 |
| 2025-06-12 | Grant or award derivative | — | 40,006 | $0.00 | 40,006 |
| 2024-09-03 | Sale | — | 40,000 | $1.71 | 1,171,543 |
| 2024-08-05 | Sale | — | 5,652 | $1.34 | 1,211,543 |
| 2024-08-02 | Sale | — | 18,933 | $1.41 | 1,217,195 |
| 2024-08-01 | Sale | — | 15,415 | $1.50 | 1,236,128 |
| 2024-07-02 | Sale | — | 8,652 | $1.34 | 1,251,543 |
| 2024-07-01 | Sale | — | 31,348 | $1.45 | 1,260,195 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Whitehawk Therapeutics’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Neil Desai · this page | Executive Chairman | $2,162,314 |
| David Lennon | President and Chief Executive Officer | $2,135,688 |
| Scott Giacobello | Chief Financial Officer and Former Interim President and Chief Executive Officer | $1,971,183 |
| Brendan Delaney | Former President and Chief Executive Officer | $1,645,015 |
| Loretta Itri | Chief Medical Officer | $1,475,685 |
Board service
Whitehawk Therapeutics board · FY2023–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $40,000 | $0 | $57,968 | $0 | $97,968 |
| FY2023 | — | — | — | — | — |
Each year as the company reported it in Whitehawk Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Whitehawk Therapeutics pays directors a $40,000 cash retainer and $58,000 in Options. As stated in Whitehawk Therapeutics's FY2025 proxy.
The full Whitehawk Therapeutics compensation record
free company briefThis page is one person within Whitehawk Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Whitehawk Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.